Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Preferred Shares (2021 - 2025)

Coeptis Therapeutics Holdings has reported Preferred Shares over the past 3 years, most recently at $1.0 for Q2 2025.

  • Quarterly results put Preferred Shares at $1.0 for Q2 2025, down 50.0% from a year ago — trailing twelve months through Jun 2025 was $1.0 (down 50.0% YoY), and the annual figure for FY2024 was $2.0, changed.
  • Preferred Shares for Q2 2025 was $1.0 at Coeptis Therapeutics Holdings, roughly flat from $1.0 in the prior quarter.
  • Over the last five years, Preferred Shares for COEPW hit a ceiling of $2.0 in Q2 2024 and a floor of $1.0 in Q4 2021.
  • Median Preferred Shares over the past 3 years was $1.5 (2021), compared with a mean of $1.5.
  • Peak annual rise in Preferred Shares hit 50.0% in 2025, while the deepest fall reached 50.0% in 2025.
  • Coeptis Therapeutics Holdings' Preferred Shares stood at $1.0 in 2021, then skyrocketed by 100.0% to $2.0 in 2024, then crashed by 50.0% to $1.0 in 2025.
  • The last three reported values for Preferred Shares were $1.0 (Q2 2025), $1.0 (Q1 2025), and $2.0 (Q4 2024) per Business Quant data.